AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
AIM ImmunoTech (NYSE:AIM) announced the closing of its rights offering on March 6, 2026, which generated approximately $1.8 million in total subscriptions. Each purchased Unit was priced at $1,000 and consisted of one share of Series G convertible preferred stock and 2,000 Class G warrants.
The offering used a Form S-1 registration (No. 333-292085) declared effective by the SEC on February 10, 2026, with a prospectus supplement filed February 27, 2026. Maxim Group acted as dealer-manager.
AIM ImmunoTech (NYSE American: AIM) announced preliminary results of a rights offering that expired March 3, 2026, estimating aggregate subscriptions of approximately $1.8 million.
The offering sold Units at $1,000 per Unit (one Series G convertible preferred share plus 2,000 Class G warrants). Closing is anticipated on or about March 6, 2026, subject to customary conditions.
AIM ImmunoTech (NYSE American: AIM) signed an agreement with the PPD clinical research business of Thermo Fisher Scientific to design an anticipated Phase 3 trial of Ampligen for late-stage pancreatic cancer on March 2, 2026. AIM said its ongoing Phase 2 DURIPANC study with durvalumab is showing positive progress in PFS, OS and safety.
The Phase 2 study is investigator-initiated, open-label and expected to enroll up to 25 subjects in its Phase 2 portion; AIM plans to work with Thermo Fisher on Phase 3 design as enrollment completes later this year.
AIM ImmunoTech (NYSE:AIM) updated terms of its previously announced rights offering and reminded stockholders that the subscription period expires March 3, 2026 at 5:00 p.m. ET. Each subscription right now purchases one Unit for $1,000, consisting of one share of Series G Convertible Preferred Stock and 2,000 Class G common warrants.
Each Preferred share is convertible into 1,000 common shares (conversion price $1.00). Each warrant is exercisable for one common share at $1.00 per share and expires five years after issuance. Rights are non-transferable and exercise is irrevocable. The offering is made under an effective Form S-1 declared effective Feb. 10, 2026.
AIM ImmunoTech (NYSE American: AIM) extended the subscription period for its previously announced rights offering to 5:00 p.m. ET on March 3, 2026. The offering commenced on February 11, 2026 and subscription rights are non-transferable and exercisable only during the subscription period.
The company stated the SEC declared its Form S-1 effective on February 10, 2026. Maxim Group LLC is engaged as dealer-manager and Broadridge will act as subscription agent for receipt of completed rights certificates and payment.
AIM ImmunoTech (NYSE American: AIM) announced planned milestones and timelines for the Phase 2 DURIPANC study testing Ampligen (rintatolimod) with AstraZeneca’s durvalumab (Imfinzi) in metastatic pancreatic cancer.
Key items: 18 subjects enrolled to date; enrollment completion planned July 2026; full Ampligen dosing by August 2026; primary endpoint readout (6-month clinical benefit rate) in December 2026; secondary endpoint evaluations by June 2027. AIM published an updated corporate presentation prioritizing Ampligen approval in pancreatic cancer.
AIM ImmunoTech (NYSE American: AIM) commenced a rights offering distributing non-transferable Subscription Rights to holders of record as of Feb 10, 2026 to purchase up to 12,000 Units at $1,000 per Unit, implying $12.0 million gross proceeds if fully subscribed.
Each Unit includes one share of Series G convertible preferred (convertible into 833 common shares) and 1,666 five-year warrants exercisable at $1.20 per share. Subscription Period runs from Feb 11–27, 2026 (expected expiration 5:00 p.m. ET Feb 27, 2026).
AIM ImmunoTech (NYSE American: AIM) will host a live virtual investor Closing Bell event on Thursday, February 19, 2026 at 4:00 PM ET featuring CEO Thomas K. Equels. The presentation will focus on the lead drug Ampligen and the ongoing DURIPANC trial combining Ampligen with AstraZeneca's Imfinzi for metastatic pancreatic cancer.
A live video webcast will be available on the company Events page, with a replay posted two hours after the live presentation and accessible for 90 days.
AIM ImmunoTech (NYSE American: AIM) has commenced a rights offering to sell up to 12,000 Units at $1,000 per Unit, targeting aggregate gross proceeds of $12.0 million. Each Unit consists of one share of Series G convertible preferred stock and 1,666 warrants.
Each preferred share converts into 833 common shares (conversion price $1.20); each warrant is exercisable for one common share at $1.20 through five years. Subscription rights are non-transferable and expire at 5:00 p.m. ET on February 27, 2026, unless extended.
AIM ImmunoTech (NYSE American: AIM) will participate in the Corporate Connect Webinar Series hosted by Webull Financial, held virtually February 10-11, 2026. CEO Thomas K. Equels will present a corporate overview and business outlook with emphasis on AIM's strategic focus on pancreatic cancer.
Presentation details: Wednesday, February 11, 2026 at 1:40 PM EST; registration and current corporate presentation on Ampligen breakthroughs are available.